Italy's AIFA explains importance of generics and biosimilars for healthcare

12 January 2016

Generic and biosimilar medicines represent an essential opportunity to optimize the efficiency of healthcare systems in Italy, according to an article published this week in the Journal of Generic Medicines, Generic and Biosimilar Medicines Use and Expenditure: A Report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA).

The article signed by Alessandro Monaco from the AIFA highlights the opportunity for generic and biosimilar medicines to enable access and meet the growing demand of healthcare systems in terms of the effectiveness of therapies and to address the sustainability of healthcare budgets. The AIFA also underlines the importance of generic and biosimilar competition for the overall sustainability of healthcare systems.

Welcomed by Assogenerici DG

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK